Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Rhea-AI Summary
Precigen (Nasdaq: PGEN) announced it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. A conference call to discuss the results will be held at 4:30 PM ET, with access details available on the company’s investor website.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report: PGEN +8.28% in the Jul 21 session
In the Jul 21 session, PGEN gained 8.28%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.9% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings date notice | Neutral | +1.4% | Scheduled first-quarter 2026 results and a 4:30 PM ET conference call. |
| Mar 11 | Earnings date notice | Neutral | -4.1% | Scheduled full-year 2025 results and a 4:30 PM ET conference call. |
| Nov 06 | Earnings date notice | Neutral | -0.5% | Scheduled third-quarter 2025 results and a 4:30 PM ET conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings-date notices produced mixed reactions, with two negative moves and one positive move; the reported average move was -1.05%.
Key Terms
commercial-stage technical
immuno-oncology medical
proof-of-concept technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The conference call may be accessed by dialing 1-800-836-8184 (
Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results including the Company's ability to reach cash flow break-even, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-announce-second-quarter-2026-financial-results-and-provide-business-updates-on-august-4-302830158.html
SOURCE Precigen, Inc.